Loading...
Loading...
All product recalls associated with Turkana Food Inc..
Total Recalls
1000
Past Year
742
Class I (Serious)
175
Most Recent
Jan 2026
Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.
Product tested positive for Salmonella
This recall involves Pearhead Learning Sets with model number 87150. The Learning Sets are sold in a box with the words "learning set developmental toys for babies 0-6 months." The eight-piece Learning Sets include a cow stroller toy, crinkle sheep toy, black and white tummy time book with flashcards, plush activity cube and a wooden egg shaker rattle. The model number is printed on the side of the package under the bar code.
Increase in complaints concerning "pullwire" breakage that may result in the broken pullwire remaining in the anchor implant body after deployment.
PACCAR Incorporated (PACCAR) is recalling certain 2025 Kenworth T180, Peterbilt 535, 567, 2025-2026 Kenworth T280, 2023-2026 Kenworth T380, 2024-2026 Kenworth T480, 2024-2026 Peterbilt 536, 537, and 548 trucks. The exterior lighting switch may fail, resulting in the hazard lights and the instrument display back-light brightness adjustment not functioning. As such, these vehicles fail to comply with the requirements of Federal Motor Vehicle Safety Standard (FMVSS) numbers 101, "Control and Displays" and 108, "Lamps, Reflective Devices and Associated Equipment."
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Failed Impurities/Degradation Specifications
CGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.